Evidence map›Paper›PMID 24063415›Full record

ArticleNanomedicine (London, England)2014

Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells.

Wenxue Chen, Ciceron Ayala-Orozco, Nrusingh C Biswal, Carlos Perez-Torres, Marc Bartels, Rizia Bardhan, Gary Stinnet, Xian-De Liu, Baoan Ji, Amit Deorukhkar and 6 more

Open access · greenAbstract read
In one paragraph

Article in Nanomedicine (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Protease-Sensitive Nanomaterials for Cancer Therapeutics and Imaging.Industrial & engineering chemistry research · 2017
    Review
  12. Review
  13. Gold nanoparticles enlighten the future of cancer theranostics.International journal of nanomedicine · 2017
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Wenxue ChenDivision of Molecular Imaging, Department of Radiology, Baylor College of Medicine, Mail: BCM 360, One Baylor Plaza, Houston, TX 77030, USA and Department of Diagnostic Imaging, The Fourth Hospital of Hebei Medical University/Hebei Province Tumor Hospital, 12 Jiankang Road, Shijiazhuang, Hebei Province 050011, China.
Ciceron Ayala-Orozco
Nrusingh C Biswal
Carlos Perez-Torres
Marc Bartels
Rizia Bardhan
Gary Stinnet
Xian-De Liu
Baoan Ji
Amit Deorukhkar
Lisa V Brown
Sushovan Guha
Robia G Pautler
Sunil Krishnan
Naomi J Halas
Amit Joshi
Baylor College of Medicine · USRice University · USThe University of Texas MD Anderson Cancer Center · USFourth Hospital of Hebei Medical University · CNMayo Clinic · US

Funding

Diabetes Endocrinology Research CenterP30DK079638 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI CHAN, LAWRENCE · 2008 to 2012
$6.4M
Preclinical platform for theranostic nanoparticles in pancreatic cancerU01CA151886 · NCI · RICE UNIVERSITY · PI HALAS, NANCY J · 2010 to 2014
$1.7M
Molecularly guided multimodal theranostics for breast cancerR01CA151962 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI JOSHI, AMIT · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA151962NCI NIH HHS R01CA151962NCI NIH HHS U01 CA151886NIDDK NIH HHS P30 DK079638NIDDK NIH HHS P30DK079638
6 · The paper itself

Abstract

aimWe report a magneto-fluorescent theranostic nanocomplex targeted to neutrophil gelatinase-associated lipocalin (NGAL) for imaging and therapy of pancreatic cancer. MATERIALS &

methodsGold nanoshells resonant at 810 nm were encapsulated in silica epilayers doped with iron oxide and the near-infrared (NIR) dye indocyanine green, resulting in theranostic gold nanoshells (TGNS), which were subsequently conjugated with antibodies targeting NGAL in AsPC-1-derived xenografts in nude mice.

resultsAnti-NGAL-conjugated TGNS specifically targeted pancreatic cancer cells in vitro and in vivo providing contrast for both NIR fluorescence and T2-weighted MRI with higher tumor contrast than can be obtained using long-circulating, but nontargeted, PEGylated nanoparticles. The nanocomplexes also enabled highly specific cancer cell death via NIR photothermal therapy in vitro.

conclusionTGNS with embedded NIR and magnetic resonance contrasts can be specifically targeted to pancreatic cancer cells with expression of early disease marker NGAL, and enable molecularly targeted imaging and photothermal therapy.

Indexed as

Acute-Phase ProteinsAnimalsCell Line, TumorContrast MediaDrug Delivery SystemsFemaleFluorescent DyesGoldHumansHyperthermia, InducedLipocalin-2LipocalinsMagnetic Resonance ImagingMagnetsMice, NudeNanoshellsAcute-Phase ProteinsContrast MediaFluorescent DyesGoldLcn2 protein, mouseLipocalin-2LipocalinsOncogene ProteinsMRInanoshellsnoninvasive imagingoptical imagingpancreatic cancerphotothermal

Identifiers

PMID24063415
PMCPMC4051872
OpenAlexW2156631561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.